JAK2 and myeloproliferative neoplasm: In the MPN group, 39 cases (71%) contained a JAK2 V617F mutation, 12 cases (22%) a CALR mutation, 2 cases (4%) an MPL mutation, 1 case (2%) was triple negative, and in 1 case, the driver mutation could not be determined due to insufficient DNA quality.